Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).
Monitoring nebuliser usage & lung function in clinical trials.
Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack).
